IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of rhIL-11, when given
subcutaneously for six consecutive months, in reducing menstrual blood loss in women with
type 1 von Willebrand disease and refractory menorrhagia. Efficacy will be measured by
subjective bleeding severity scale and pictorial bleeding chart. Safety will be measured by
the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias,
fluid retention, or edema.
Phase:
Phase 2
Details
Lead Sponsor:
Margaret Ragni University of Pittsburgh
Collaborators:
University of North Carolina Wyeth is now a wholly owned subsidiary of Pfizer